You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of the First-ever Safe and Effective Anterior Chamber Paracentesis Instrument to Treat and Diagnose Ocular Diseases
SBC: F SQUARE MEDICAL LLC Topic: 100PROJECT SUMMARY Despite advances in the treatment of ocular diseases, vision-threatening disease or eye injury remain the top 10 disabilities among adults. Several of these ocular conditions require an anterior chamber paracentesis (ACP). ACP is clinically indicated to reduce acutely elevated intraocular pressure (IOP) to avoid risk of permanent vision loss and to sample aqueous humor for disease ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
PKU Now-Connect: An intelligent digital ecosystem to improve health outcomes in Phenylketonuria
SBC: ANALYTICAL DIAGNOSTIC SOLUTIONS INC Topic: 107AbstractPhenylketonuria (PKU) is an inherited genetic disorder that results in an inability to metabolize the essential amino acid phenylalanine (Phe). Consequences of uncontrolled blood Phe include intellectual disabilities, seizures, skin disorders, tremors, hyperactivity, EEG abnormalities, behavioral problems, executive dysfunction, and psychiatric disorders. PKU affects approximately 1 in 24, ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Plans4Care: Personalized Dementia Care On-Demand
SBC: Plans4Care INC Topic: RPROJECT ABSTRACT Although rt11 million family/friends are caregivers to rt6 million people with Alzheimer's Disease (AD) and AD- Related Dementias (AD/ADRD), they do not typically receive personalized education, strategies and support to manage their own wellbeing and complex dementia-related symptoms. Lack of personalized care contributes to $321 billion annually in AD/ADRD care costs. In respons ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Low-Cost, Single-Use Trans-Nasal Cryotherapy Device for Low-Resource Settings
SBC: RAHIMZADEH JASON Topic: 102PROJECT SUMMARY/ABSTRACT Esophageal cancer is an aggressive disease with a five-year survival rate below 20 percent. The incidence of this cancer has increased dramatically over the last 50 years and is projected to continue increasing at least until 2030. Chronic acid reflux leads to changes in the lining of the esophagus and the development of Barrett’s Esophagus in some patients. Patients wit ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis
SBC: OAK THERAPEUTICS INC Topic: NIAIDPROJECT SUMMARY Tuberculosis (TB) remains one of the major sources of mortality from infectious diseases worldwide. In 2021 an estimated 6.4 million were newly diagnosed with TB globally, approximately 10.6 million fell ill from it, and 1.4 million died from the disease. Of those who died from the disease, 54% were men, 32% women, and 14% were children aged lt15 years. TB is also a leading cause o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis
SBC: Prokaryotics, Inc. Topic: NIAIDWidespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a n ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Beat Extreme: An Interactive, Tailored Text Messaging Program Combining Extreme Weather Alerts with Hyper-localized Resources and Actionable Insights for Addressing Climate Change
SBC: Pro-Change Behavior Systems, Inc. Topic: RSummary Climate change is an urgent public health threat, and climate-related health risks disproportionately impact vulnerable populations. Public health agencies have underscored the need to develop scalable and innovative health-equity centered, multi-level interventions that offer tools and resources to 1) raise awareness of the inextricable link between climate change and health and 2) suppor ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Functionalized Multi-Modal Tetrode Arrays for Real-Time, Site-Specific Neurochemical Monitoring
SBC: Pinnacle Technology, Inc. Topic: 101ABSTRACT The goal of this proposal is to develop a multimodal, multianalyte sensor system including wired and wireless electronics and software. This new suite of tools will enable simultaneous recording of amperometric sensors (glutamate, glucose, lactate, choline, and/or oxygen), electrophysiology, and fast-scan cyclic voltammetry (biogenic amines) in conscious, freely moving rodents. The propos ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Machine Learning Phenotypic De Novo Drug Design
SBC: PGI HOLDING CORPORATION Topic: 101PROJECT SUMMARY The high rate of failure in CNS drug discovery, in particular of the first-in-class therapeutics with new modes of action, highlights a clear unmet need to improve the success rate in drug discovery for psychiatric disorders. One well-known issue is the poor ability of current bioassays and animal models to predict the efficacy and side- effects of compounds. Another important issu ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
New 5HT2AR Target Identification and Assay Development for Discovering Psychoplastogenic Compounds
SBC: BIOINVENU CORPORATION Topic: NIDASpecific Aim: New 5HT2AR/14-3-3 isoform signal pathway identification and assay development for discovering psychoplastogenic compounds. Significance: Emerging data and limited clinical results show the promise of psychedelic drugs in the durable relief of people from seemingly untreatable psychiatric disorders and drug addictions. Neuroimaging evidence supports the concept that the brain after a ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health